143 mSIPS-dNLR identifies patients unlikely to respond to first-line pembrolizumab for advanced non-small cell lung cancer
Author:
Benjamin Jia Liang Lim,Elliot Erskine,Nicholas Fethers,Jenny Lamb,Irfaan Mohangee,Karim H. El-Shakankery,Jack Leach,Barry J.A. Laird,Christina Lilley,Sally Clive,Colin Barrie,Jane Parry,Almudena Cascales,Michael Yule,Leo R. Brown,Marie Fallon et al.
Copyright © 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.